Relmada names Bipin Dalmia as Chief Business Officer

Relmada Therapeutics announced on July 28, 2026 that it has appointed Bipin Dalmia, PhD, MBA, as Chief Business Officer. Relmada is a clinical-stage biotechnology company advancing therapies for oncology and central nervous system disorders.¹ In his new role, Dalmia will oversee corporate strategy, commercial planning, and business development for the company, and will report to CEO Sergio Traversa.¹

The company said the appointment reflects Relmada's move toward late-stage development and its effort to build commercial and strategic capabilities to maximize the value of NDV-01¹, its sustained-release intravesical therapy for non-muscle invasive bladder cancer (NMIBC).

Dalmia brings nearly three decades of biopharmaceutical experience. Most recently, he was Senior Vice President and Global Head of Portfolio Strategy and Business Development at Ferring Pharmaceuticals, a newly created function he built from the ground up.¹ Over his 14 years at Ferring, he also led the company's Uro-Oncology Franchise, overseeing the U.S. launch and global lifecycle and manufacturing strategy for ADSTILADRIN, described as the first FDA-approved intravesical gene therapy for BCG-unresponsive NMIBC.¹ He completed more than 20 licensing, partnership, and M&A transactions across therapeutic areas and modalities during his tenure.¹

Earlier in his career, Dalmia held business development roles at Biolex Therapeutics, and worked in strategy and new product planning at Syngenta and Novartis.¹ He currently sits on the boards of Ferring Ventures S.A. and FinVector Oy.¹ He holds a PhD and MS in Chemical Engineering from Iowa State University and an MBA from Drake University.¹

Relmada's lead programs, NDV-01 and sepranolone, are currently in mid-stage clinical development.¹